nuclear matrix protein 2

03/01/2023 - "Anti-nuclear matrix protein 2 (NXP2) antibody is a rare myositis-specific antibody. "
03/12/2021 - "Meanwhile, anti-nuclear matrix protein 2 (NXP2) antibody was strongly positive in the idiopathic inflammatory myopathy (IIM) spectrum test from the serum. "
01/01/2019 - "Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts."
03/01/2021 - "The objectives of this study are to analyze the association between anti-nuclear matrix protein 2 (NXP2) autoantibody and idiopathic inflammatory myopathies (IIMs) and to assess the diagnostic and prognostic relevance of anti-NXP2 autoantibody in patients with IIMs. "
01/01/2018 - "Differential Clinical Associations of Anti-Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies."

01/01/2019 - "The aim of this study was to evaluate the association of anti-nuclear matrix protein 2 antibody (anti-NXP2) with calcinosis, ILD and malignancy in IIM patients. "
01/01/2022 - "Computed tomography-like magnetic resonance images based on T1 spoiled gradient-echo to detect calcinosis in a patient with anti-nuclear matrix protein 2 antibody-positive juvenile dermatomyositis."
01/01/2022 - "The anti-nuclear matrix protein 2 (NXP2) antibody, a MSA detected in juvenile/adult IIMs, has been reported to be associated with a high risk of subcutaneous calcinosis, subcutaneous oedema and internal malignancies. "
01/01/2021 - "Multivariate analysis showed that a younger age at disease onset [odds ratio (OR) = 0.945, 95% CI 0.925, 0.966, P < 0.001], dysphagia (OR = 2.609, 95% CI 1.189, 5.728, P = 0.017), skin ulcer (OR = 5.705, 95% CI 3.041, 10.705, P < 0.001) and the presence of anti-nuclear matrix protein 2 antibody (OR = 5.917, 95% CI 2.754, 12.714, P < 0.001) were independently associated with calcinosis. "
12/01/2022 - "The presence of nuclear matrix protein 2 (NXP-2) autoantibodies is predominantly associated with joint contractures and calcinosis. "

01/01/2019 - "The aim of this study was to evaluate the association of anti-nuclear matrix protein 2 antibody (anti-NXP2) with calcinosis, ILD and malignancy in IIM patients. "
11/15/2022 - "Anti-nuclear matrix protein 2 (NXP2) antibody was found in her sera and a diagnosis of cancer-associated dermatomyositis was thus made. "
01/01/2022 - "The anti-nuclear matrix protein 2 (NXP2) antibody, a MSA detected in juvenile/adult IIMs, has been reported to be associated with a high risk of subcutaneous calcinosis, subcutaneous oedema and internal malignancies. "
12/01/2022 - "Antibodies against Nuclear Matrix Protein 2 are also potentially associated with increased cancer emergence in dermatomyositis. "
10/01/2018 - "Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay."

03/01/2023 - "Expanding the clinical phenotype of nuclear matrix protein 2 antibody-positive dermatomyositis."
11/24/2021 - "[Anti-nuclear matrix protein 2 antibody-positive dermatomyositis with the preferential involvement of neck extensors: a case report]."
09/01/2021 - "Unique cutaneous features in a case of anti-nuclear matrix protein 2 antibody positive-dermatomyositis."
04/21/2021 - "[A case of dermatomyositis positive for anti-nuclear matrix protein 2 antibody without dermatologic symptoms]."
01/06/2021 - "To summarize the characteristics of gastrointestinal (GI) perforation in anti-nuclear matrix protein 2 (NXP2) antibody-associated juvenile dermatomyositis (JDM). "

01/01/2019 - "Patients with positive nuclear matrix protein 2 autoantibodies had strong MxA expression, whereas anti-melanoma differentiation-associated gene 5 positive patients had no or weak MxA expression. "
07/01/2023 - "This review summarized the classic biomarkers of PM/DM, including anti-aminoacyl tRNA synthetases (ARS) antibody, anti-Mi-2 antibody, anti-melanoma differentiation-associated gene 5 (MDA5) antibody, anti-transcription intermediary factor 1-γ (TIF1-γ) antibody, anti-nuclear matrix protein 2 (NXP2) antibody, among others. "
01/01/2020 - "These patients underwent full investigation for DM-specific autoantibodies (against transcriptional intermediary factor γ, Mi-2, melanoma differentiation-associated gene 5, nuclear matrix protein 2 [NXP-2], and small ubiquitin-like modifier activating enzyme ); however, 17 patients were excluded because their muscle fibers did not express myxovirus resistance protein A, a sensitive and specific marker of DM muscle pathology. "
07/01/2023 - "In dermatomyositis, five disease-specific autoantibodies have been established to date, including antiMi-2, anti-melanoma differentiation-associated gene 5, anti-transcriptional intermediary factor 1, anti-nuclear matrix protein 2, anti-transcriptional intermediary factor 1, and anti-small-ubiquitin-like activating enzyme antibodies. "
01/01/2022 - "Of these, 249 patients were positive for 1 of the 5 DMSAs (seropositive patients: 87 anti-transcription intermediary factor 1-γ [TIF1-γ], 40 anti-complex nucleosome remodeling histone deacetylase [Mi-2], 29 anti-melanoma differentiation gene 5 [MDA5], 83 anti-nuclear matrix protein 2 [NXP-2], and 10 anti-small ubiquitin-like modifier-activating enzyme [SAE] dermatomyositis) and 7 patients were negative for all 5 DMSAs (seronegative patients). "